Advertisement
Organisation › Details
Axol Bioscience (Group)
Axol Bioscience is the leading provider of human iPSC-based products and services, to build more relevant models of human disease that expand understanding and de-risk drug development. We support researchers and the biopharma industry with three main offerings: a commercial library of 70 human iPSCs (axoLines™); iPSC-derived cells (axoCells™); and custom research capabilities (axoServices™) comprising gene editing, electrophysiology, reprogramming and differentiation. At Axol, we've built a reputation for quality and consistency, manufacturing our products under stringent ISO 9001:2015 quality measures with robust scientific expertise and functional data. With over a decade of scientific expertise, a strong company culture and a global network of collaborators, we've become the industry leaders in using human iPSCs to drive better human disease models. *
Start | 2013-04-01 established | |
Industry | iPSC technology (induced pluripotent stem cell technology) | |
Industry 2 | stem cell research | |
Person | Taylor, Liam (Axol Bioscience 202008– CEO before BBI Solutions) | |
Person 2 | Shi, Yichen (Axol Bioscience 201304– CEO + Co-founder) | |
Region | Cambridge, Cambridgeshire | |
Country | United Kingdom (GB) | |
Street | The Science Village, Suite 3 Chesterford Research Park | |
City | CB10 1XL Little Chesterford, Cambridgeshire | |
Tel | +44-1223-751051 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Axol Bioscience Ltd.. (6/7/23). "Press Release: Axol Bioscience Collaborates with StrataStem to Deliver Stem Cell Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease". Cambridge, Edinburgh & Alderley Park. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Axol Bioscience (Group)
- [1] Axol Bioscience Ltd.. (6/7/23). "Press Release: Axol Bioscience Collaborates with StrataStem to Deliver Stem Cell Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease". Cambridge, Edinburgh & Alderley Park....
- [2] Axol Bioscience Ltd.. (4/7/22). "Press Release: Axol Bioscience Raises £3.2 Million GBP (c. $4.2 Million USD)". Cambridge....
- [3] DefiniGen Ltd.. (1/20/22). "Press Release: DefiniGen Appoints Dr Chris Kirton as Chief Executive Officer". Cambridge....
- [4] Axol Bioscience Ltd.. (3/17/21). "Press Release: Axol Bioscience and Censo Biotechnologies Announce Merger". Cambridge....
- [5] Axol Bioscience Ltd.. (10/13/20). "Press Release: Axol Bioscience Introduces Multi-electrode Array Screening Services for Human iPSC-derived Cells". Cambridge....
- [6] Axol Bioscience Ltd.. (8/27/20). "Press Release: Axol Bioscience Appoints Liam Taylor as Chief Executive Officer". Cambridge....
- [7] Axol Bioscience Ltd.. (7/17/18). "Press Release: Axol Bioscience Launch Human iPSC-derived Atrial Cardiomyocytes". Cambridge....
- [8] Zyme Communications Ltd.. (8/1/17). "Press Relase: Zyme Communications Strengthens Team and Relocates Cambridge Office". Cambridge....
- [9] Evotec AG. (6/28/17). "Press Release: Evotec Expands iPSC Drug Discovery Leadership through Strategic Collaboration with Censo Biotechnologies". Hamburg....
- [10] Cellectricon AB. (1/26/17). "Press Release: Cellectricon and Censo Biotechnologies Introduce a Joint Technology Access Program Utilizing High-quality Human iPSC-based Discovery Services for CNS and Pain Research". Mölndal & Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top